Coping with the Data Avalanche

Nice Insight

The Data Generation

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Big Data: A Big Challenge

Nigel Walker

Nice Insight

Energizing Client Portfolios with Patient-Friendly Dosage Forms

Don Barbieri

SPI Pharma

Continuous Manufacturing: To Be Continued…

Guy Tiene; Roger Viney; Bal Kalirai, Ph.D.; Lukas Utiger, Ph.D; Mark Griffiths; Ian Muir, Ph.D.; Matt Hanson

Nice Insight

Industry Benchmark: Introduction

Nice Insight

Changes in the Wind for the CDMO Market

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch; Carrie Cao, Ph.D.

Nice Insight

Spending on Contract Research Services Slowing Down

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch; Nice Insight; Carrie Cao, Ph.D.

Nice Insight

Investors May Look Smaller

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch; Nice Insight; Carrie Cao, Ph.D.

Nice Insight

Equipment Must Integrate

Steve Kuehn; Emilie Branch; Nice Insight; Carrie Cao, Ph.D.

Nice Insight

Spending on Excipients Grows & Diversifies

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch; Nice Insight; Carrie Cao, Ph.D.

Nice Insight

Keeping the Chain Going

Steve Kuehn; Cynthia A. Challener, Ph.D.; Emilie Branch; Nice Insight; Carrie Cao, Ph.D.

Nice Insight

Growth Anticipated for Intermediates

Steve Kuehn; Emilie Branch; Nice Insight; Carrie Cao, Ph.D.

Nice Insight

2017 Top 5 Industry Leader

Nice Insight

Operational Excellence in Outsourced Fill-Finish Services

Guy Tiene; Oskar Gold

Nice Insight

Expanding the Commercial Options for Preparation of Amorphous Solid Dispersions

Márcio Temtem, Ph.D.; João Vicente, Ph.D.

Hovione

Q: How is the Need to Provide Local Drug-Product Supply in Multiple Regions Around the World Impacting Pharmaceutical Manufacturing Facility and Equipment Design?

Pharma's Almanac

Q: What Do CROs/CDMOs Need to Do to Ensure That They Provide Effective Global Support but with Locally Oriented Services?

Pharma's Almanac

Q: What will be the Impact of the Requirements that Drug Manufacturers Gain a Similar Level of Supply Chain Understanding for Excipients as they Must Have for APIs?

William van den Bremer; Ramesh Subramanian, Ph.D.; Dirk Hair; Patricia Rafidison

DFE Pharma

Q: What are the Greatest Challenges Drug Manufacturers Face When Working to Meet the New Requirements for Excipient Supply Chain Security?

Pharma's Almanac